Foley Hoag Represents Arsanis in $45M Series D Financing

May 10, 2017

Foley Hoag LLP recently represented Arsanis, Inc. in the closing of its $45.5 million Series D financing. Arsanis is a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and post-infection treatment of serious infectious diseases. The company is headquartered in Waltham, MA, with European research and preclinical development operations in Vienna, Austria.

The financing allows Arsanis to focus on completing its ongoing Phase 2 study for ASN100, a potential new standard of care for the prevention of Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company also plans to continue to advance its preclinical gram-negative programs and respiratory syncytial virus program toward the clinic.

The investment was led by the Bill & Melinda Gates Foundation, with additional participation by several new investors, including GV (formerly Google Ventures), Alexandria Venture.  The company’s existing investors, including OrbiMed, Polaris Venture Partners, SV Health Investors, NeoMed, EMBL Ventures and the Anna Maria and Stephen Kellen Foundation also took part in the round.

Foley Hoag attorneys Robert Birnbaum, Karen Tepichin, Patrick Connolly and Remi Kathawa represented Arsanis in the matter.